JP2008538173A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008538173A5 JP2008538173A5 JP2007553353A JP2007553353A JP2008538173A5 JP 2008538173 A5 JP2008538173 A5 JP 2008538173A5 JP 2007553353 A JP2007553353 A JP 2007553353A JP 2007553353 A JP2007553353 A JP 2007553353A JP 2008538173 A5 JP2008538173 A5 JP 2008538173A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- luca2
- tumor
- antibody
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64900705P | 2005-01-31 | 2005-01-31 | |
| PCT/US2006/003382 WO2006083852A2 (en) | 2005-01-31 | 2006-01-31 | Luca2 and antibodies that bind thereto |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008538173A JP2008538173A (ja) | 2008-10-16 |
| JP2008538173A5 true JP2008538173A5 (https=) | 2009-03-05 |
Family
ID=36777832
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007553353A Pending JP2008538173A (ja) | 2005-01-31 | 2006-01-31 | Ｌｕｃａ２およびそれに結合する抗体 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US7847070B2 (https=) |
| EP (1) | EP1846032A4 (https=) |
| JP (1) | JP2008538173A (https=) |
| CA (1) | CA2596115A1 (https=) |
| WO (1) | WO2006083852A2 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2009258063B2 (en) | 2007-06-21 | 2014-09-25 | Macrogenics, Inc. | BCR-complex-specific antibodies and methods of using same |
| US8241861B1 (en) | 2008-07-08 | 2012-08-14 | Insilicos, Llc | Methods and compositions for diagnosis or prognosis of cardiovascular disease |
| EP2376109B1 (en) | 2008-12-19 | 2019-01-23 | MacroGenics, Inc. | Covalent diabodies and uses thereof |
| US8709816B2 (en) | 2009-09-04 | 2014-04-29 | Tohoku University | Human renal disease marker substance |
| JP5998060B2 (ja) | 2010-03-04 | 2016-09-28 | マクロジェニクス，インコーポレーテッド | Ｂ７−ｈ３と反応性のある抗体、その免疫学的に活性なフラグメントおよびその使用 |
| PH12012501751A1 (en) | 2010-03-04 | 2012-11-12 | Macrogenics Inc | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| EP2601216B1 (en) | 2010-08-02 | 2018-01-03 | MacroGenics, Inc. | Covalent diabodies and uses thereof |
| CA2836873C (en) | 2011-05-21 | 2019-10-22 | Macrogenics, Inc. | Deimmunized serum-binding domains and their use for extending serum half-life |
| US9487587B2 (en) | 2013-03-05 | 2016-11-08 | Macrogenics, Inc. | Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof |
| EP3152235B1 (en) | 2014-05-29 | 2021-08-25 | MacroGenics, Inc. | Tri-specific binding molecules and methods of use thereof |
| WO2017019846A1 (en) | 2015-07-30 | 2017-02-02 | Macrogenics, Inc. | Pd-1-binding molecules and methods use thereof |
| US10954301B2 (en) | 2015-12-14 | 2021-03-23 | Macrogenics, Inc. | Bispecific molecules having immunoreactivity with PD-1 and CTLA-4, and methods of use thereof |
| TWI781098B (zh) | 2016-04-15 | 2022-10-21 | 美商宏觀基因股份有限公司 | 新穎的ｂ７-ｈ３-結合分子、其抗體藥物綴合物及其使用方法 |
| IL268836B2 (en) | 2017-02-24 | 2024-04-01 | Macrogenics Inc | Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof |
| SG11202005557TA (en) | 2017-12-12 | 2020-07-29 | Macrogenics Inc | Bispecific cd 16-binding molecules and their use in the treatment of disease |
| SG11202007572VA (en) | 2018-02-15 | 2020-09-29 | Macrogenics Inc | Variant cd3-binding domains and their use in combination therapies for the treatment of disease |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US43029A (en) * | 1864-06-07 | Improvement in explosive projectiles for ordnance | ||
| US16006A (en) * | 1856-11-04 | Kocking-chaik | ||
| US3862925A (en) | 1973-07-05 | 1975-01-28 | American Home Prod | Preparation of somatotropin release inhibiting factor and intermediates therefor |
| US3842067A (en) | 1973-07-27 | 1974-10-15 | American Home Prod | Synthesis of(des-asn5)-srif and intermediates |
| JPS5726506B2 (https=) | 1974-03-08 | 1982-06-04 | ||
| US4105603A (en) | 1977-03-28 | 1978-08-08 | The Salk Institute For Biological Studies | Peptides which effect release of hormones |
| USRE30548E (en) | 1979-08-31 | 1981-03-17 | The Salk Institute For Biological Studies | Peptides which effect release of hormones |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6054561A (en) | 1984-02-08 | 2000-04-25 | Chiron Corporation | Antigen-binding sites of antibody molecules specific for cancer antigens |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US6020145A (en) | 1989-06-30 | 2000-02-01 | Bristol-Myers Squibb Company | Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96 |
| US5552391A (en) | 1990-01-16 | 1996-09-03 | La Jolla Pharmaceutical Company | Chemically-defined non-polymeric valency platform molecules and conjugates thereof |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| GB9115364D0 (en) | 1991-07-16 | 1991-08-28 | Wellcome Found | Antibody |
| AU669124B2 (en) | 1991-09-18 | 1996-05-30 | Kyowa Hakko Kirin Co., Ltd. | Process for producing humanized chimera antibody |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| US5753229A (en) * | 1991-09-25 | 1998-05-19 | Mordoh; Jose | Monoclonal antibodies reactive with tumor proliferating cells |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US6180377B1 (en) | 1993-06-16 | 2001-01-30 | Celltech Therapeutics Limited | Humanized antibodies |
| US5532159A (en) | 1994-04-01 | 1996-07-02 | The Ohio State University | Monoclonal antibody to canine placental oncofetal protein for detecting cancer |
| US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
| EP1473301A3 (en) | 1997-06-04 | 2005-01-26 | Cornell Research Foundation, Inc. | Betulinol derivatives |
| US6406840B1 (en) | 1999-12-17 | 2002-06-18 | Biomosaic Systems, Inc. | Cell arrays and the uses thereof |
| AU7333701A (en) * | 2000-07-10 | 2002-01-21 | Univ Texas | Chromosome 3p21.3 genes are tumor suppressors |
| US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
| MXPA04012664A (es) | 2002-06-19 | 2005-08-15 | Raven Biotechnologies Inc | Objetivo de superficie celular raag10 novedoso y una familia de anticuerpos que reconocen ese objetivo. |
| US6682904B1 (en) * | 2002-08-15 | 2004-01-27 | Deliatroph Pharmaceuticals, Inc. | Specific inhibitors of hyaluronidase 2, and methods of identifying and using same |
| ES2437491T3 (es) * | 2003-10-10 | 2014-01-10 | Alchemia Oncology Pty Limited | Modulación de la síntesis y degradación de hialuronano en el tratamiento de enfermedad |
| JP2006014694A (ja) * | 2004-07-05 | 2006-01-19 | Mitsubishi Kagaku Iatron Inc | ペプチド、その抗体及びその抗体の製法 |
-
2006
- 2006-01-31 EP EP06719967A patent/EP1846032A4/en not_active Withdrawn
- 2006-01-31 WO PCT/US2006/003382 patent/WO2006083852A2/en not_active Ceased
- 2006-01-31 CA CA002596115A patent/CA2596115A1/en not_active Abandoned
- 2006-01-31 US US11/344,814 patent/US7847070B2/en not_active Expired - Fee Related
- 2006-01-31 JP JP2007553353A patent/JP2008538173A/ja active Pending
-
2010
- 2010-10-29 US US12/915,842 patent/US20110045006A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010508847A5 (https=) | ||
| JP2008538173A5 (https=) | ||
| JP2008532488A5 (https=) | ||
| JP2008529494A5 (https=) | ||
| JP2005532050A5 (https=) | ||
| US20260027225A1 (en) | Monoclonal antibodies specific for fibroblast growth factor receptor 4 (fgfr4) and methods of their use | |
| JP7682789B2 (ja) | Ｂ７－Ｈ３のＩｇＶドメインに対するモノクローナル抗体及びその使用 | |
| JP2010110329A5 (https=) | ||
| AU2025201864A1 (en) | Anti-cd24 compositions and uses thereof | |
| CN111183156A (zh) | 用于用抗cd19/cd20免疫治疗来治疗癌症的组合物和方法 | |
| JP2020501531A5 (https=) | ||
| JP2008508858A5 (https=) | ||
| JP2007532139A5 (https=) | ||
| JP2010510809A5 (https=) | ||
| JP2008529497A5 (https=) | ||
| JP2008526256A5 (https=) | ||
| JP2005538701A5 (https=) | ||
| JP2012503203A5 (https=) | ||
| CN107108741B (zh) | 与l1cam(cd171)结合的结合分子，特别是抗体 | |
| JPWO2019224717A5 (https=) | ||
| TW202146456A (zh) | 抗ｃｄ７１抗體類、可活化之抗ｃｄ７１抗體類及使用彼等之方法 | |
| JP2009297037A5 (https=) | ||
| JP2018508214A5 (https=) | ||
| JP2007532566A5 (https=) | ||
| Germain et al. | MHC class I–related chain A conjugated to antitumor antibodies can sensitize tumor cells to specific lysis by natural killer cells |